$LGND Balance Sheet | Understand Stock

$LGND

$311.73 +$3.43 (1.11%) Close

$LGND Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated balance sheets

In millions of USD; shares in millions, except per-share amounts

	Q2 FY2026 As of Jun 30, 2026	Q1 FY2026 As of Mar 31, 2026	Q4 FY2025 As of Dec 31, 2025	Q3 FY2025 As of Sep 30, 2025	Q2 FY2025 As of Jun 30, 2025	Q1 FY2025 As of Mar 31, 2025	Q4 FY2024 As of Dec 31, 2024	Q3 FY2024 As of Sep 30, 2024	Q2 FY2024 As of Jun 30, 2024	Q1 FY2024 As of Mar 31, 2024	Q4 FY2023 As of Dec 31, 2023	Q3 FY2023 As of Sep 30, 2023	Q2 FY2023 As of Jun 30, 2023	Q1 FY2023 As of Mar 31, 2023	Q4 FY2022 As of Dec 31, 2022	Q3 FY2022 As of Sep 30, 2022	Q2 FY2022 As of Jun 30, 2022	Q1 FY2022 As of Mar 31, 2022	Q4 FY2021 As of Dec 31, 2021	Q3 FY2021 As of Sep 30, 2021
ASSETS
Current assets:
Cash and cash equivalents
Short-term investments
Accounts receivable, net
Inventory
Short-term portion of financial royalty assets, net
Income taxes receivable
Current derivative assets
Prepaid expenses
Other current assets
Current assets of discontinued operations
Assets held for sale (Note 2)
Total current assets

Intangible assets, net
Goodwill
Commercial license and other economic rights
Long-term portion of financial royalty assets, net
Noncurrent derivative assets
Property and equipment, net
Lease right-of-use assets
Finance lease right-of-use assets
Equity method investments
Equity securities in Primrose Bio
Other investments
Deferred income taxes, net
Other assets
Non-current assets of discontinued operations
Total assets

LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable
Accrued liabilities
Income taxes liability
Income taxes payable
Deferred revenue
Current contingent liabilities
Current operating lease liabilities
Current finance lease liabilities
2023 convertible senior notes, net
Current liabilities of discontinued operations
Liabilities related to assets held for sale (Note 2)
Other current liabilities
Total current liabilities

2023 convertible senior notes, net
Long-term deferred revenue
Long-term contingent liabilities
Long-term operating lease liabilities
Convertible senior notes, net
Deferred income taxes, net
Other long-term liabilities
Non-current liabilities of discontinued operations
Total liabilities
Stockholders’ equity:
Preferred stock, $0.001 par value; 5,000 shares authorized; zero issued and outstanding at June 30, 2026 and December 31, 2025
Common stock, $0.001 par value; 60,000 shares authorized; 19,920 and 19,774 shares issued and outstanding at June 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated other comprehensive income
Retained earnings
Total stockholders’ equity
Total liabilities and stockholders’ equity

Common Stock, Shares, Issued

Comments